Oral cancer chemoprevention - The end of EPOC, the beginning of an epoch of molecular selection

JAMA Oncology

Volumn 2, Issue 2, 2016, Pages 178-179

  Bauman, Julie E ^a   Grandis, Jennifer ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ERLOTINIB; PROTEIN KINASE INHIBITOR;

FEMALE; HUMAN; MALE; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS;

ANTICARCINOGENIC AGENTS; ERLOTINIB HYDROCHLORIDE; FEMALE; HUMANS; MALE; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; PROTEIN KINASE INHIBITORS;

EID: 84976582488     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.4637     Document Type: Editorial

References (9)

1. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6(5):963-968.
2. William WN, Papadimitrakopoulou V, Lee JJ, et al. Erlotinib and the risk of oral cancer: the erlotinib prevention of oral cancer (EPOC) randomized clinical trial [published online November 5, 2015]. JAMA Oncol. doi:10.1001/jamaoncol.2015.4364.
3. Mao L, El-Naggar AK, Papadimitrakopoulou V, et al. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst. 1998;90(20):1545-1551.
4. Papadimitrakopoulou VA, Lee JJ, William WN Jr, et al. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol. 2009;27(4):599-604.
5. Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res. 2000;6(2):357-362.
6. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 1990;323(12):795-801.
7. Khuri FR, Lee JJ, Lippman SM, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst. 2006;98(7):441-450.
8. Taoudi Benchekroun M, Saintigny P, Thomas SM, et al. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila). 2010;3(7):800-809.
9. Leeman-Neill RJ, Seethala RR, Singh SV, et al. Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma. Cancer Prev Res (Phila). 2011;4(2):230-237.